Capecitabine Accord

<p>Capecitabine Accord is a cancer medicine that is used to treat:</p><ul><li>colon (large bowel) cancer. Capecitabine Accord is used on its own or with other cancer medicines in patients who have had surgery for stage III or Dukes’ stage C colon cancer;</li><li>metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body). Capecitabine Accord is used on its own or with other cancer medicines;</li><li>advanced gastric (stomach) cancer. Capecitabine Accord is used with other cancer medicines, including a platinum-containing cancer medicine such as cisplatin;</li><li>locally advanced or metastatic breast cancer (breast cancer that has begun to spread to other parts of the body). Capecitabine Accord is used with docetaxel (another cancer medicine) after treatment with anthracyclines (another type of cancer medicine) has failed. It can also be used on its own when treatment with both anthracyclines and taxanes (another type of cancer medicine) has failed or when further treatment with anthracyclines is not suitable for the patient.</li></ul><p>Capecitabine Accord is a ‘generic’ and a ‘hybrid’ medicine. This means that it is similar to a ‘reference medicine’, but it contains capecitabine at a new strength in addition to existing strengths. While the reference medicine, Xeloda, is available as 150 and 500 mg tablets, Capecitabine Accord is also available as 300 mg tablets.</p><p>Capecitabine Accord contains the active substance capecitabine.</p>